<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078923</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353197</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2418</secondary_id>
    <nct_id>NCT00078923</nct_id>
  </id_info>
  <brief_title>Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate</brief_title>
  <official_title>Phase II Clinical Trial of Soy Isoflavones Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent or delay the
      development of early cancer. Soy isoflavones may be effective in delaying the development of
      early prostate cancer.

      PURPOSE: This randomized phase II trial is studying different regimens of soy isoflavones to
      compare how well they work in treating patients who are undergoing radical prostatectomy for
      stage I or stage II prostate cancer (adenocarcinoma).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare blood/prostate biomarkers of oxidative stress and prostate cancer risk in
           patients with stage I or II adenocarcinoma of the prostate treated with 3 different dose
           levels of soy isoflavones before radical prostatectomy.

        -  Compare prostatic tissue biomarkers of proliferation and apoptosis in patients treated
           with these regimens.

        -  Determine the potential response, in terms of tumor and prostatic intraepithelial
           neoplasia grade and volume, extraprostatic extension, and serum prostate-specific
           antigen level, in patients treated with soy isoflavones and in those treated with
           placebo.

        -  Determine the safety of soy isoflavone supplementation in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel-group study.
      Patients are stratified according to tumor stage (T1c vs T2). Patients are randomized to 1 of
      4 treatment arms.

        -  Arm I (control group): Patients receive oral placebo once daily.

        -  Arm II: Patients receive oral soy isoflavones and oral placebo once daily.

        -  Arm III: Patients receive a higher dose of oral soy isoflavones and oral placebo once
           daily.

        -  Arm IV: Patients receive a higher dose (higher than arm III) of oral soy isoflavones
           once daily.

      In all arms, treatment continues for 2-6 weeks (depending on the time from study entry to
      planned surgery) in the absence of unacceptable toxicity. All patients then undergo radical
      prostatectomy.

      Patients are followed at 1 week.

      PROJECTED ACCRUAL: A total of 100 patients (25 per treatment arm) will be accrued for this
      study within 12.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative DNA damage as measured by 5-hydroxymethyluridine level</measure>
    <time_frame>at 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid oxidation as measured by 8-isoprostane level</measure>
    <time_frame>at 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor size, grade, and extension</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen and prostatic intraepithelial neoplasia grade</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of cell growth, differentiation, and apoptosis</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by number and grade of adverse events</measure>
    <time_frame>at 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavones</intervention_name>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Prostatectomy or Brachytherapy</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Soy isoflavones and placebo</arm_group_label>
    <arm_group_label>Soy Isoflavones/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Stage T1c or T2

               -  Disease confined to the prostate gland

          -  Planning to undergo radical prostatectomy within the next 3-4 weeks

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  ALT and AST less than 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 2 times ULN

        Renal

          -  Not specified

        Other

          -  Fertile patients must use effective barrier contraception

          -  Medically cleared for surgery

          -  No concurrent thyroid disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior biological therapy for prostate cancer

          -  No concurrent biological agents

        Chemotherapy

          -  No prior chemotherapy for prostate cancer

          -  No concurrent chemotherapy

        Endocrine therapy

          -  No prior hormonal therapy for prostate cancer

          -  No concurrent thyroid hormone replacement medication

          -  No concurrent hormonal therapy

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

        Other

          -  At least 3 months since prior high-dose nutritional supplements

          -  No concurrent regular use (more than once weekly) of soy products greater than 50 g of
             soy protein or 50 mg of soy isoflavone

          -  No concurrent high-dose nutritional supplements

               -  Standard-dose single multivitamin tablet (e.g., Centrumâ„¢) allowed

          -  No concurrent herbs

          -  No concurrent soy foods

          -  No other concurrent isoflavone supplements

          -  No other concurrent antineoplastic agents
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Kucuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

